Neurocrine Biosciences Inc has a consensus price target of $159.84 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $114 issued by BMO Capital on October 17, 2024. The 3 most-recent analyst ratings were released by Needham, RBC Capital, and UBS on April 15, 2025, April 14, 2025, and April 4, 2025, respectively. With an average price target of $137.33 between Needham, RBC Capital, and UBS, there's an implied 35.46% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/15/2025 | Buy Now | 36.12% | Needham | Ami Fadia51% | → $138 | Upgrade | Hold → Buy | Get Alert |
04/14/2025 | Buy Now | 35.14% | RBC Capital | Brian Abrahams47% | $138 → $137 | Upgrade | Sector Perform → Outperform | Get Alert |
04/04/2025 | Buy Now | 35.14% | UBS | Ashwani Verma40% | $154 → $137 | Maintains | Buy | Get Alert |
03/26/2025 | Buy Now | 81.5% | JP Morgan | Anupam Rama56% | $183 → $184 | Maintains | Overweight | Get Alert |
03/07/2025 | Buy Now | 47.96% | Morgan Stanley | Jeffrey Hung50% | $185 → $150 | Assumes | → Overweight | Get Alert |
02/24/2025 | Buy Now | 82.48% | HC Wainwright & Co. | Andrew Fein54% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
02/21/2025 | Buy Now | 82.48% | HC Wainwright & Co. | Andrew Fein54% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
02/10/2025 | Buy Now | 60.78% | Guggenheim | Yatin Suneja47% | $165 → $163 | Maintains | Buy | Get Alert |
02/10/2025 | Buy Now | 82.48% | HC Wainwright & Co. | Andrew Fein54% | $190 → $185 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | 45.99% | RBC Capital | Brian Abrahams47% | $154 → $148 | Maintains | Sector Perform | Get Alert |
02/07/2025 | Buy Now | 45% | Wedbush | Laura Chico44% | $157 → $147 | Maintains | Outperform | Get Alert |
02/07/2025 | Buy Now | 60.78% | Canaccord Genuity | Sumant Kulkarni41% | $172 → $163 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | 82.48% | HC Wainwright & Co. | Andrew Fein54% | $190 → $185 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | Hold → Hold | Get Alert |
02/07/2025 | Buy Now | 76.56% | B of A Securities | Tazeen Ahmad55% | $184 → $179 | Maintains | Buy | Get Alert |
02/04/2025 | Buy Now | 82.48% | Morgan Stanley | Jeffrey Hung50% | $170 → $185 | Maintains | Overweight | Get Alert |
01/30/2025 | Buy Now | 73.6% | UBS | Ashwani Verma40% | $162 → $176 | Maintains | Buy | Get Alert |
01/08/2025 | Buy Now | 59.79% | UBS | Ashwani Verma40% | $142 → $162 | Maintains | Buy | Get Alert |
12/23/2024 | Buy Now | 57.82% | Piper Sandler | David Amsellem69% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
12/23/2024 | Buy Now | 62.75% | Barclays | Carter Gould56% | $160 → $165 | Maintains | Overweight | Get Alert |
12/20/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | Hold → Hold | Get Alert |
12/16/2024 | Buy Now | 45.99% | Wedbush | Laura Chico44% | $148 → $148 | Reiterates | Outperform → Outperform | Get Alert |
12/16/2024 | Buy Now | 87.41% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
11/11/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
11/01/2024 | Buy Now | 87.41% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
10/31/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
10/30/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
10/29/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
10/17/2024 | Buy Now | 12.45% | BMO Capital | Evan Seigerman64% | $128 → $114 | Maintains | Market Perform | Get Alert |
10/10/2024 | Buy Now | 52.89% | Raymond James | Danielle Brill41% | → $155 | Reinstates | → Outperform | Get Alert |
10/08/2024 | Buy Now | 31.19% | RBC Capital | Brian Abrahams47% | $133 → $133 | Reiterates | Sector Perform → Sector Perform | Get Alert |
10/04/2024 | Buy Now | 31.19% | RBC Capital | Brian Abrahams47% | $136 → $133 | Maintains | Sector Perform | Get Alert |
09/16/2024 | Buy Now | 52.89% | Cantor Fitzgerald | Charles Duncan68% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
09/09/2024 | Buy Now | 57.82% | Barclays | Carter Gould56% | $180 → $160 | Maintains | Overweight | Get Alert |
08/29/2024 | Buy Now | 52.89% | Cantor Fitzgerald | Charles Duncan68% | $170 → $155 | Maintains | Overweight | Get Alert |
08/29/2024 | Buy Now | 26.26% | BMO Capital | Evan Seigerman64% | $142 → $128 | Maintains | Market Perform | Get Alert |
08/29/2024 | Buy Now | 56.84% | Piper Sandler | David Amsellem69% | $131 → $159 | Upgrade | Neutral → Overweight | Get Alert |
08/29/2024 | Buy Now | 34.15% | RBC Capital | Brian Abrahams47% | $143 → $136 | Maintains | Sector Perform | Get Alert |
08/29/2024 | Buy Now | 87.41% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
08/29/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
08/19/2024 | Buy Now | 86.43% | Jefferies | Akash Tewari43% | $177 → $189 | Maintains | Buy | Get Alert |
08/07/2024 | Buy Now | 78.54% | JP Morgan | Anupam Rama56% | $173 → $181 | Maintains | Overweight | Get Alert |
08/05/2024 | Buy Now | 87.41% | HC Wainwright & Co. | Andrew Fein54% | $160 → $190 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 41.05% | RBC Capital | Brian Abrahams47% | $136 → $143 | Maintains | Sector Perform | Get Alert |
08/02/2024 | Buy Now | 77.55% | Guggenheim | Yatin Suneja47% | $170 → $180 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 55.85% | Citigroup | David Hoang35% | $150 → $158 | Maintains | Neutral | Get Alert |
08/02/2024 | Buy Now | 116.02% | Oppenheimer | Jay Olson61% | $216 → $219 | Maintains | Outperform | Get Alert |
08/02/2024 | Buy Now | 77.55% | Barclays | Carter Gould56% | $169 → $180 | Maintains | Overweight | Get Alert |
08/02/2024 | Buy Now | 77.55% | Baird | Brian Skorney57% | $157 → $180 | Maintains | Outperform | Get Alert |
08/01/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
07/25/2024 | Buy Now | 52.89% | Cantor Fitzgerald | Charles Duncan68% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
07/25/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
07/12/2024 | Buy Now | 67.69% | Morgan Stanley | Jeffrey Hung50% | $160 → $170 | Maintains | Overweight | Get Alert |
07/10/2024 | Buy Now | 70.65% | JP Morgan | Anupam Rama56% | $169 → $173 | Maintains | Overweight | Get Alert |
06/12/2024 | Buy Now | 57.82% | Morgan Stanley | Jeffrey Hung50% | $160 → $160 | Maintains | Overweight | Get Alert |
05/29/2024 | Buy Now | 49.93% | Wedbush | Laura Chico44% | $152 → $152 | Reiterates | Outperform → Outperform | Get Alert |
05/28/2024 | Buy Now | 90.37% | UBS | Ashwani Verma40% | $174 → $193 | Maintains | Buy | Get Alert |
05/14/2024 | Buy Now | 72.62% | Evercore ISI Group | Cory Kasimov68% | → $175 | Initiates | → Outperform | Get Alert |
05/03/2024 | Buy Now | 47.96% | Citigroup | David Hoang35% | $140 → $150 | Maintains | Neutral | Get Alert |
05/02/2024 | Buy Now | 61.77% | Canaccord Genuity | Sumant Kulkarni41% | $154 → $164 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 67.69% | Guggenheim | Yatin Suneja47% | $164 → $170 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 66.7% | Barclays | Carter Gould56% | $150 → $169 | Maintains | Overweight | Get Alert |
05/02/2024 | Buy Now | 36.12% | BMO Capital | Evan Seigerman64% | $129 → $138 | Maintains | Market Perform | Get Alert |
05/02/2024 | Buy Now | 113.06% | Oppenheimer | Jay Olson61% | $200 → $216 | Maintains | Outperform | Get Alert |
05/02/2024 | Buy Now | 57.82% | HC Wainwright & Co. | Andrew Fein54% | $150 → $160 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
05/01/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
04/24/2024 | Buy Now | 47.96% | HC Wainwright & Co. | Andrew Fein54% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
04/24/2024 | Buy Now | 67.69% | Wells Fargo | Mohit Bansal69% | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
04/24/2024 | Buy Now | 97.28% | Oppenheimer | Jay Olson61% | $200 → $200 | Maintains | Outperform | Get Alert |
04/23/2024 | Buy Now | — | Needham | Ami Fadia51% | — | Reiterates | → Hold | Get Alert |
04/17/2024 | Buy Now | 45% | Wedbush | Laura Chico44% | $147 → $147 | Reiterates | Outperform → Outperform | Get Alert |
04/10/2024 | Buy Now | 52.89% | Cantor Fitzgerald | Charles Duncan68% | → $155 | Reiterates | Overweight → Overweight | Get Alert |
03/20/2024 | Buy Now | 55.85% | JP Morgan | Anupam Rama56% | $148 → $158 | Maintains | Overweight | Get Alert |
03/13/2024 | Buy Now | 97.28% | Oppenheimer | Jay Olson61% | $170 → $200 | Maintains | Outperform | Get Alert |
02/23/2024 | Buy Now | 45.99% | JP Morgan | Anupam Rama56% | $154 → $148 | Maintains | Overweight | Get Alert |
02/08/2024 | Buy Now | 38.09% | Citigroup | David Hoang35% | $141 → $140 | Maintains | Neutral | Get Alert |
02/08/2024 | Buy Now | 38.09% | Mizuho | Uy Ear60% | $116 → $140 | Maintains | Neutral | Get Alert |
02/08/2024 | Buy Now | 38.09% | Wells Fargo | Mohit Bansal69% | $127 → $140 | Maintains | Equal-Weight | Get Alert |
01/25/2024 | Buy Now | 50.92% | Goldman Sachs | Chris Shibutani55% | $134 → $153 | Maintains | Buy | Get Alert |
01/23/2024 | Buy Now | 47.96% | Barclays | Carter Gould56% | $145 → $150 | Maintains | Overweight | Get Alert |
12/18/2023 | Buy Now | 42.04% | Stifel | Paul Matteis41% | $141 → $144 | Maintains | Buy | Get Alert |
12/13/2023 | Buy Now | 25.27% | Wells Fargo | Mohit Bansal69% | $110 → $127 | Maintains | Equal-Weight | Get Alert |
12/13/2023 | Buy Now | 25.27% | Citigroup | David Hoang35% | → $127 | Initiates | → Neutral | Get Alert |
12/12/2023 | Buy Now | 34.15% | Deutsche Bank | Neena Bitritto-Garg59% | → $136 | Initiates | → Buy | Get Alert |
12/07/2023 | Buy Now | 47.96% | Canaccord Genuity | Sumant Kulkarni41% | → $150 | Reiterates | Buy → Buy | Get Alert |
11/10/2023 | Buy Now | -1.36% | BMO Capital | Evan Seigerman64% | $111 → $100 | Maintains | Market Perform | Get Alert |
11/10/2023 | Buy Now | 19.35% | RBC Capital | Brian Abrahams47% | $128 → $121 | Maintains | Sector Perform | Get Alert |
11/10/2023 | Buy Now | 12.45% | Mizuho | Uy Ear60% | $116 → $114 | Maintains | Neutral | Get Alert |
11/03/2023 | Buy Now | 14.42% | Mizuho | Uy Ear60% | $113 → $116 | Maintains | Neutral | Get Alert |
11/01/2023 | Buy Now | 26.26% | RBC Capital | Brian Abrahams47% | $123 → $128 | Maintains | Sector Perform | Get Alert |
11/01/2023 | Buy Now | -1.36% | Piper Sandler | David Amsellem69% | $95 → $100 | Maintains | Neutral | Get Alert |
11/01/2023 | Buy Now | 43.03% | Raymond James | Danielle Brill41% | $135 → $145 | Maintains | Outperform | Get Alert |
10/24/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | — | Assumes | → Overweight | Get Alert |
10/06/2023 | Buy Now | 62.75% | Oppenheimer | Jay Olson61% | $160 → $165 | Maintains | Outperform | Get Alert |
10/06/2023 | Buy Now | 47.96% | HC Wainwright & Co. | Andrew Fein54% | $146 → $150 | Maintains | Buy | Get Alert |
09/13/2023 | Buy Now | 42.04% | Canaccord Genuity | Sumant Kulkarni41% | $132 → $144 | Maintains | Buy | Get Alert |
09/13/2023 | Buy Now | 11.46% | Mizuho | Uy Ear60% | → $113 | Reiterates | Neutral → Neutral | Get Alert |
09/13/2023 | Buy Now | 35.14% | Wedbush | Laura Chico44% | $120 → $137 | Maintains | Outperform | Get Alert |
09/13/2023 | Buy Now | 32.18% | JP Morgan | Anupam Rama56% | $133 → $134 | Maintains | Overweight | Get Alert |
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Needham on April 15, 2025. The analyst firm set a price target for $138.00 expecting NBIX to rise to within 12 months (a possible 36.12% upside). 71 analyst firms have reported ratings in the last year.
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Needham, and Neurocrine Biosciences upgraded their buy rating.
The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.
There is no last downgrade for Neurocrine Biosciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a upgraded with a price target of $0.00 to $138.00. The current price Neurocrine Biosciences (NBIX) is trading at is $101.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.